Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.062 CHF | +4.73% | -6.63% | +34.78% |
Jun. 06 | Transcript : Addex Therapeutics Ltd, Q1 2024 Earnings Call, Jun 06, 2024 | |
Jun. 06 | Addex Therapeutics' Q1 Net Loss Widens; Revenue Down | MT |
Sales 2024 * | 1.5M 1.68M | Sales 2025 * | 1.5M 1.68M | Capitalization | 7.95M 8.88M |
---|---|---|---|---|---|
Net income 2024 * | -4M -4.47M | Net income 2025 * | -3M -3.35M | EV / Sales 2024 * | 2.45 x |
Net cash position 2024 * | 4.27M 4.77M | Net Debt 2025 * | 710K 792K | EV / Sales 2025 * | 5.77 x |
P/E ratio 2024 * |
-1.03
x | P/E ratio 2025 * |
-1.24
x | Employees | 23 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.28% |
Latest transcript on Addex Therapeutics Ltd
1 day | +4.73% | ||
1 week | -6.63% | ||
Current month | -13.41% | ||
1 month | -15.07% | ||
3 months | -20.51% | ||
6 months | +37.78% | ||
Current year | +34.78% |
Managers | Title | Age | Since |
---|---|---|---|
Tim Dyer
FOU | Founder | 56 | 01-12-31 |
Lénaic Teyssédou
DFI | Director of Finance/CFO | 38 | 17-05-31 |
Vincent Lawton
CHM | Chairman | 75 | 09-04-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jake Nunn
BRD | Director/Board Member | 53 | 18-05-31 |
Tim Dyer
FOU | Founder | 56 | 01-12-31 |
Vincent Lawton
CHM | Chairman | 75 | 09-04-15 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-12 | 0.062 | +4.73% | 169,657 |
24-06-11 | 0.0592 | -15.19% | 1,291,731 |
24-06-10 | 0.0698 | +12.58% | 474,290 |
24-06-07 | 0.062 | -6.63% | 212,312 |
24-06-06 | 0.0664 | 0.00% | 54,257 |
Delayed Quote Swiss Exchange, June 12, 2024 at 11:30 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.78% | 8.92M | |
+48.54% | 56.61B | |
+37.15% | 39.25B | |
-6.02% | 39.62B | |
-6.90% | 28.28B | |
+12.97% | 26.44B | |
-16.91% | 20.12B | |
+31.71% | 12.48B | |
+28.18% | 12.51B | |
+0.38% | 12.2B |
- Stock Market
- Equities
- ADXN Stock